New data published by the National Institute for Health and Care Research shows a major acceleration in the UK’s ability to recruit patients into commercial international clinical trials, reinforcing the country’s position as a global leader in life sciences research.
Between April 2025 and March 2026, UK research sites recruited 100 global or European ‘first participants’ into commercial international studies – almost double the 53 firsts achieved during the previous year.
A global first means a UK site was the first in the world to enrol a participant into an international study, while a European first indicates the first enrolment anywhere in Europe.
Of the 100 milestones achieved this year, 32 were global firsts, and 68 were European firsts. England accounted for 95 of these achievements, with Scotland delivering the remaining five.
Sustained growth in early trial recruitment
The latest figures continue a strong upward trend. Three years ago, the UK recorded just 18 first participant recruitments in commercial international studies. This rose to 46 in 2024, 53 in 2025, and has now reached 100 in 2026 – representing more than a five‑fold increase since 2023.
During the same period, the National Institute for Health and Care Research (NIHR) recorded 591 commercial international studies opening across the UK. Nearly 17% of these studies successfully recruited a global or European first participant, underlining the country’s growing capability to deliver complex trials at speed.
Faster set‑up times drive results
Rapid recruitment has been enabled by significant improvements in trial set‑up times. The average time to set up a commercial trial fell to 122 days this year, down from 169 days the previous year.
This progress moves the UK closer to the government’s 150‑day target, which aims to ensure that 95% of clinical trials are set up and ready to recruit within 150 days or fewer. The target is central to strengthening the UK’s attractiveness to international life sciences investment.
Making participation easier for patients
At the same time, taking part in research has become easier for the public. The NIHR’s Be Part of Research service allows people to register online and be matched to suitable studies based on their interests, conditions and location – helping to widen access and diversify participation.
UK leads on complex early‑phase trials
The data also highlights the UK’s growing strength in delivering complex, early‑phase trials. In March 2026, the Newcastle Advanced Therapy Treatment Centre became the first site globally to activate the CHILL trial.
The CHILL study, sponsored by Quell Therapeutics, is a Phase 1/2 trial evaluating a pioneering cell therapy for refractory rheumatoid arthritis and systemic sclerosis. Running across three countries, the trial saw the UK activate three sites ahead of schedule, putting the country two months ahead of its European counterparts.
Supported by the NIHR Industry Hub and the wider UK life sciences ecosystem, the first UK site enrolled its initial participant just 113 days after starting the set‑up process.
Why global ‘firsts’ matter
Recruiting the first participant in a global or European trial is a key indicator for international sponsors. It demonstrates that a country’s regulatory, NHS and research systems are working efficiently and collaboratively.
These achievements help attract global investment into the UK life sciences sector, supporting NHS research infrastructure, boosting economic growth and giving UK patients earlier access to innovative treatments that may not yet be widely available.
Dr Maria Koufali, NIHR Life Sciences Industry Director, commented:
“For 3 consecutive years, the UK has delivered year-on-year growth in commercial clinical research activity. This latest data shows that UK clinical trials delivery is not just improving-it is being fundamentally transformed.
“Through strong government leadership, national coordination, and system-wide reform, the UK is becoming faster, more predictable, and increasingly attractive for global life sciences investment.”
The government remains committed to achieving the 150‑day set‑up target. By streamlining approvals and strengthening collaboration between the NIHR and the NHS, the UK continues to accelerate the journey from laboratory discovery to patient care.
Ultimately, this progress is about making a tangible difference for patients and the public – while ensuring the health and care workforce is supported to innovate today, for the benefit of future generations.
Image credit: iStock
